DIAD: Division of Immunotherapy for Autoimmune Diseases
Feinburg School of Medicine
HOME
ABOUT DIAD
WHO WE ARE
Richard K. Burt, MD
Faculty & Staff
Other DIAD Sites
THERAPIES & RESEARCH
Clinical Trials
Transplant Overview
NEWS & PUBLICATIONS
Videos
Articles
Publications
Stories of Hope
HOW YOU CAN HELP
Donate
Spread the Word
CONTACT US
PATIENTS
THERAPIES & RESEARCH: Clinical Trials
Bookmark and Share

Since its establishment, basic and clinical research has been an integral part of the Division of Immunotherapy and Autoimmune Diseases (DIAD) at Northwestern University. Our physicians are world leaders in the areas of stem cell research and clinical trials.

We are committed to finding answers to today's most disabling and puzzling medical problems. Working collaboratively with the scientists of Northwestern University Feinberg School of Medicine, our physicians are translating exciting research advances discovered in the laboratory into more effective treatment approaches and prevention strategies for our patients.

To learn more about our stem cell research and immunotherapy,
please contact us: 312- 695 - 4960.

For information on National Institute of Health sponsored Clinical Trials at Northwestern University, ClinicalTrials.gov offers easy access to information on clinical trials on a wide variety of diseases and conditions.
For Additional Northwestern Feinberg School of Medicine research information, visit Northwestern Center for Clinical Research — Patient Overview
Information for Patients >

About the Multiple Sclerosis (MS) Trial:
Multiple sclerosis (MS) is an autoimmune disease in which the nerves of the central nervous system (brain and spinal cord) degenerate. Multiple Sclerosis is at onset an immune-mediated disease. In most cases, it starts as a relapsing—remitting disease with distinct attacks and no progression between flares. Over time, most cases transition into a progressive disease which means a slow neurologic deterioration without acute flares . Relapsing remitting disease is often responsive to immune–based therapies while, in general, it is ineffective in the more severe progressive stages of the disease.


Northwestern University, the University of Calgary and the University of Sao Paulo, Brazil have partnered to offer patients with relapsing-remitting inflammatory MS, a randomized study utilizing autologous stem cell transplantation versus the FDA approved standard of care (i.e. interferon, Copaxone®, mitoxantrone or Tysabri®)
View the study design >

 
© 2010 Division of Immunotherapy AND Autoimmune Diseases (DIAD)
Feinberg School of Medicine Northwestern Memorial Hospital Northwestern University